Neos Therapeutics Announces Issuance Of Key Patent Covering Its Extended Release Oral Disintegrating Tablet (XR-ODT) Platform Technology

DALLAS & FORT WORTH, Texas--(BUSINESS WIRE)--Neos Therapeutics, Inc. (“Neos”), a specialty pharmaceutical company with a portfolio of novel and proprietary oral drug delivery technologies as well as a late-stage pipeline of innovative extended release (“XR”) products for Attention Deficit Hyperactivity Disorder (“ADHD”), announced today that is has been granted a key patent (US Patent No. 8,840,924) covering its XR-oral disintegrating tablet (“ODT”) technology, known as Rapidly Disintegrating Ionic Masking™ (RDIM™).

RDIM™ utilizes an orally disintegrating, controlled release, taste-masked pharmaceutical composition that can withstand compression forces associated with standard tableting technology, allowing for a drug to be incorporated into the ODT dosage form using ion resin technology. This technology not only provides extended release or controlled release properties, it can also mask the unpleasant taste of the drugs.

Help employers find you! Check out all the jobs and post your resume.

Back to news